Skip to main content
Liminatus Pharma, Inc. logo

Liminatus Pharma, Inc. — Investor Relations & Filings

Ticker · LIMN US Manufacturing
Filings indexed 80 across all filing types
Latest filing 2026-03-31 Annual Report
Country US United States of America
Listing US LIMN

About Liminatus Pharma, Inc.

http://liminatuspharma.com/

Liminatus Pharma, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing novel, immune-modulating cancer therapies. The company specializes in immuno-oncology and is pioneering the development of a second-generation CD47-blockade antibody. This therapeutic approach is designed to utilize the patient's immune system to target and destroy cancer cells. Its lead clinical candidate, IBA101, is a humanized anti-CD47 antibody being advanced toward clinical trials for the treatment of various cancers.

Recent filings

Filing Released Lang Actions
10-K - Liminatus Pharma, Inc. (0001971387) (Filer)
Annual Report
2026-03-31 English
8-K - LIMINATUS PHARMA, INC. (0001971387) (Filer)
Regulatory Filings
2026-03-04 English
8-K Filing
Regulatory Filings
2026-02-18 English
424B4 Filing
Prospectus
2026-02-18 English
S-1 Filing
Registration Form
2026-02-11 English
8-K Filing
Regulatory Filings
2026-02-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.